<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=description content="DUBLIN, Feb. 18, 2020 /PRNewswire/ -- The &amp;quot;Global Autoinjectors Market (3rd Edition), 2020-2030&amp;quot; report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities"><meta name=author content="Martina Birk"><meta name=generator content="Hugo 0.98.0"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=robots content="index,follow,noarchive"><link rel=stylesheet href=https://assets.cdnweb.info/hugo/base16/css/style.css type=text/css><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Source+Code+Pro:400,700" type=text/css><link rel=alternate href=./index.xml type=application/rss+xml title=ZingVlog><title>Autoinjectors Industry Report, 2020-2030: Worldwide Markets, Products, Competitive &amp;amp; Patent Analyses - ZingVlog</title></head><body><header><div class="container clearfix"><a class=path href=./index.html>[ZingVlog]</a>
<span class=caret># _</span><div class=right></div></div></header><div class=container><main role=main class=article><article class=single itemscope itemtype=http://schema.org/BlogPosting><div class=meta><span class=key>published on</span>
<span class=val><time itemprop=datePublished datetime=2024-07-16>July 16, 2024</time></span>
<span class=key>in</span>
<span class=val><a href=./categories/blog>blog</a></span></div><h1 class=headline itemprop=headline>Autoinjectors Industry Report, 2020-2030: Worldwide Markets, Products, Competitive &amp;amp; Patent Analyses</h1><section class=body itemprop=articleBody><img src=https://cdn.statically.io/img/c212.net/c/img/favicon.png style=margin:auto;display:block;text-align:center;max-width:100%;height:auto><p><span class=xn-location>DUBLIN</span>, <span class=xn-chron>Feb. 18, 2020</span> /PRNewswire/ -- The "Global Autoinjectors Market (3rd Edition), 2020-2030" report has been added to <b>ResearchAndMarkets.com's</b> offering.</p><p>This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.</p><p>One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for autoinjector devices. Based on parameters, such as number of commercialized combination products, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030.</p><p><b>In order to provide a detailed future outlook, our projections have been segmented on the basis of:</b><br></p><ul type=disc><li>[A] usability (disposable and reusable)</li><li>[B] route of administration (subcutaneous and intramuscular)</li><li>[C] type of molecule (monoclonal antibody, peptide, protein and small molecule)</li><li>[D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications)</li><li>[E] key geographies (<span class=xn-location>North America</span>, <span class=xn-location>Europe</span>, <span class=xn-location>Asia-Pacific</span> and Rest of the World)</li></ul><p>More than 40% of the US population is estimated to be suffering from some form of a chronic health condition. According to the US National Health Council, over 75% of the nation's healthcare expenditure is on the treatment of chronic diseases, such as diabetes. The major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals / out-patient clinics. Over time, a variety of solutions enabling self-administration of injectable drugs have been developed and introduced into the market.</p><p>In a relatively short time period, the self-injection devices market has grown into a prominent and promising segment within the pharmaceutical industry. Autoinjectors represent one such type of device that has witnessed increased adoption among patients, especially for the treatment of emergency situations, such as anaphylactic shocks. According to developers, such devices are relatively easier to use, compared to other parenteral drug delivery systems, and have integrated needle-safety features. In fact, autoinjectors have been proven to have resolved a number of injection-related tolerability issues faced by patients.</p><p>Over the years, several players have launched proprietary autoinjectors-based combination products for use across a variety of therapeutic areas. EpiPen is one of the most popular and widely recognized autoinjectors (based on historical sales data) available in the market today. Examples of other autoinjector combination products approved in 2019 include, NUCALA Autoinjector (GlaxoSmithKline), Vyleesi Autoinjector (AMAG Pharmaceuticals / Palatin Technologies), Fasenra (AstraZeneca) and Teribone (Asahi Kasei Pharma). Autoinjectors are also considered to be a potential pharmaceutical life cycle management tool; they are used by many pharmaceutical players to expand marketing exclusivity periods of proprietary drugs.</p><p>For example, lyophilized Enbrel was reformulated for delivery via the SureClick autoinjector; this granted the drug almost 11 additional years of patent protection. It is also worth highlighting that there are a number of efforts underway to improve the existing generation of autoinjectors. Incorporation of healthcare data acquisition and analysis features, addition of smart functions to deal with medication-related errors, and improved safety measures, are some of the upgrades that device developers claim to be in the process of developing. In this context, it is worth mentioning that, so far, over 4,600 patent applications have been filed for autoinjectors and affiliated products / technologies. We believe that such efforts are likely to drive growth in this market over the coming years.</p><p><b>In addition to other elements, the study includes:</b></p><ul type=disc><li>An overview of the current market landscape of companies engaged in developing and / or manufacturing autoinjectors, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small-sized, mid-sized and large), location of headquarters and location of manufacturing facilities</li><li>Information on companies that are developing drugs in combination with autoinjectors, featuring details on initial year of approval (for marketed products), phase of development, usability of the device, route of administration (intracavernous, intramuscular and subcutaneous), type of drug molecule (antibody, peptide, protein and small molecule), dose strength, therapeutic area and other approved dosage forms (for marketed products). In addition, the section provides details on the company, including year of establishment, company size and location of headquarters</li><li>A competitiveness analysis of various disposable and reusable autoinjectors, taking into consideration supplier power (based on year of establishment and company size) and key product specifications, such as route of administration, primary drug container used, injector actuation mechanism, type of dose and user friendliness of the product.</li><li>An in-depth analysis of the various patents that have been filed/granted related to autoinjectors, till <span class=xn-chron>August 2019</span>, highlighting details on key parameters, such as type of patent, publication year, issuing authority, CPC classification, emerging focus areas and leading industry players (on the basis of number of patents). It also includes a detailed patent benchmarking and an insightful valuation analysis.</li><li>A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength and diversity of product portfolio, route of administration, actuation mechanism, geographical presence / reach and supplier power of each company.</li><li>A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future, shortlisted on the basis of an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).</li><li>A list of key opinion leaders (KOLs) within this domain who were short-listed based on their contributions (such as involvement in clinical trials and being mentioned in patent applications); it features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain.</li><li>Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records; the study provides a list of all the drugs that are currently being delivered via autoinjectors.</li><li>A case study on the role of CMOs offering services for drug delivery devices; it features a list of service providers, highlighting the various types of services offered for different types of drug-delivery devices.</li><li>A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.</li><li>Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.</li></ul><p><b>Key Topics Covered</b><br></p><p><b>1. PREFACE</b><br>1.1. Scope of the Report<br>1.2. Research Methodology<br>1.3. Chapter Outlines</p><p><b>2. EXECUTIVE SUMMARY</b></p><p><b>3. INTRODUCTION</b><br>3.1. Chapter Overview<br>3.2. Types of Drug Delivery Systems<br>3.3. Drawbacks of Conventional Parenteral Delivery Systems<br>3.4. Needlestick Injuries<br>3.4.1. Incidence and Cost Burden<br>3.4.2. Prevention<br>3.4.2.1. Government Legislation for the Prevention of Needlestick Injuries<br>3.5. Emerging Trend of Self-Administration<br>3.5.1. Rising Burden of Chronic Diseases<br>3.5.2. Healthcare Cost Savings<br>3.5.3. Need for Immediate Treatment in Emergency Situations<br>3.5.4. Growth of Injectable Biologics Market<br>3.5.5. Addressing Key User Safety Requirements<br>3.6. Types of Self-Administration Devices<br>3.6.1. Prefilled Syringes<br>3.6.2. Pen-Injectors<br>3.6.3. Needle-Free Injectors<br>3.6.4. Autoinjectors<br>3.6.5. Large Volume Wearable Injectors<br>3.7. Overview of Autoinjectors<br>3.7.1. Components of Autoinjectors<br>3.7.2. Classification of Autoinjectors<br>3.7.2.1. On the Basis of Mechanism of Action<br>3.7.2.2. On the Basis of Usability<br>3.7.2.3. On the Basis of Type of Dose<br>3.7.3. Manufacturing / Packaging of Autoinjectors<br>3.7.4. Benefits of Autoinjectors<br>3.8. Regulatory Considerations<br>3.8.1. Medical Devices<br>3.8.2. Drug Device Combination Products<br>3.9. Future Perspectives</p><p><b>4. PRIMARY DRUG CONTAINERS</b><br>4.1. Chapter Overview<br>4.2. Types of Packaging<br>4.3. Introduction to Primary Drug Containers<br>4.3.1. Role of Primary Drug Containers<br>4.3.2. Types of Primary Drug Containers<br>4.3.2.1. Cartridges<br>4.3.2.1.1. Components of Cartridges<br>4.3.2.1.2. Types of Cartridges<br>4.3.2.1.2.1. Single Chamber Cartridge<br>4.3.2.1.2.2. Dual Chamber Cartridge<br>4.3.2.1.3. Cartridges Available in the Market<br>4.3.2.2. Syringes<br>4.3.2.2.1. Components<br>4.3.2.2.2. Types of Syringes<br>4.3.2.2.2.1. Based on Number of Chambers<br>4.3.2.2.2.2. Based on Type of Needle<br>4.3.2.2.3. Prefilled Syringe Systems Available in the Market<br>4.3.2.2.3.1. Glass Prefilled Syringes<br>4.3.2.2.3.2. Plastic Prefilled Syringes<br>4.3.2.3. Vials<br>4.3.2.3.1. Components<br>4.3.2.3.2. Vials Available in the Market<br>4.4. Comparison of Fabrication Materials</p><p><b>5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE</b><br>5.1. Chapter Overview<br>5.2. Autoinjectors: List of Devices<br>5.2.1. Analysis by Usability<br>5.2.2. Analysis by Type of Primary Container<br>5.2.3. Analysis by Volume of Container<br>5.2.4. Analysis by Type of Dose<br>5.2.5. Analysis by Route of Administration<br>5.2.6. Analysis by Actuation Mechanism<br>5.2.7. Analysis by Type of Feedback Mechanism<br>5.3. Autoinjectors: List of Developers<br>5.3.1. Analysis by Year of Establishment<br>5.3.2. Analysis by Company Size<br>5.3.3. Analysis by Geographical Location of Headquarters<br>5.3.4. Analysis by Geographical Location of Manufacturing Facilities</p><p><b>6. PRODUCT COMPETITIVENESS ANALYSIS</b><br>6.1. Chapter Overview<br>6.2. Methodology<br>6.3. Assumptions and Key Parameters<br>6.4. Product Competitiveness Analysis<br>6.4.1. Disposable Autoinjectors<br>6.4.2. Reusable Autoinjectors</p><p><b>7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS</b><br>7.1. Scope and Methodology<br>7.2. Brand Positioning Matrix: Antares Pharma<br>7.3. Brand Positioning Matrix: BD<br>7.4. Brand Positioning Matrix: Elcam Drug Delivery Devices<br>7.5. Brand Positioning Matrix: Oval Medical Technologies<br>7.6. Brand Positioning Matrix: SHL Medical<br>7.7. Brand Positioning Matrix: Ypsomed<br>7.8. Brand Positioning Matrix: DALI Medical Devices</p><p><b>8. PATENT ANALYSIS</b><br>8.1. Chapter Overview<br>8.2. Scope and Methodology<br>8.3. Autoinjectors: Patent Analysis<br>8.3.1. Analysis by Publication Year<br>8.3.2. Analysis by Issuing Authority<br>8.3.3. Analysis by CPC Symbols<br>8.4. Emerging Focus Areas<br>8.5. Leading Players: Analysis by Number of Patents<br>8.6. Autoinjectors: Patent Benchmarking Analysis<br>8.6.1. Analysis by Patent Characteristics<br>8.6.2. Analysis by Geography<br>8.7. Autoinjectors: Patent Valuation Analysis</p><p><b>9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS</b><br>9.1. Chapter Overview<br>9.2. Autoinjector Combination Products: List of Approved Drugs<br>9.2.1. Analysis by Initial Year of Approval<br>9.2.2. Analysis by Usability<br>9.2.3. Analysis by Route of Administration<br>9.2.4. Analysis by Type of Molecule<br>9.2.5. Analysis by Dose Strength<br>9.2.6. Analysis by Therapeutic Area<br>9.2.7. Analysis by Other Approved Dosage Forms<br>9.3. Autoinjector Combination Products: List of Pipeline Drugs<br>9.3.1. Analysis by Phase of Development<br>9.3.2. Analysis by Route of Administration<br>9.3.3. Analysis by Type of Molecule<br>9.3.4. Analysis by Therapeutic Area<br>9.4. Autoinjector Combination Products: List of Developers<br>9.4.1. Analysis by Year of Establishment<br>9.4.2. Analysis by Company Size<br>9.4.3. Analysis by Location of Headquarters</p><p><b>10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS</b><br>10.1. Chapter Overview<br>10.2. Autoinjector-based Combination Products Available / Under Evaluation<br>10.3. Anaphylaxis<br>10.3.1. Overview and Epidemiology<br>10.3.2. Available Treatment Options: Adrenaline<br>10.3.2.1. Mechanism of Action<br>10.3.2.2. History of Development<br>10.3.3.3. Marketed Autoinjectors<br>10.3.3.3.1. Adrenaclick<br>10.3.3.3.2. Allerject / Auvi-Q (Formerly called e-cue)<br>10.3.3.3.3. Anapen<br>10.3.3.3.4. Emerade<br>10.3.3.3.5. EpiPen / EpiPen Jr<br>10.3.3.3.6. Jext<br>10.3.3.3.7. EpiPen / EpiPen Jr<br>10.3.3.4. Pipeline Autoinjectors<br>10.3.3.4.1. EpiQ<br>10.3.3.4.2. ANDIPen<br>10.3.3.4.3. MiniEpi<br>10.3.3.4.4. Zeneo Adrenaline<br>10.3.3.5. Other Dosage Forms<br>10.3.3.6. Historical Sales of Approved Products<br>10.4. Multiple Sclerosis<br>10.4.1. Overview and Epidemiology<br>10.4.2. Available Treatment Options: Interferon -1a and Interferon <span class=xn-money>-1b</span><br>10.4.2.1. Mechanism of Action<br>10.4.2.2. History of Development<br>10.4.2.3. Interferon -1a Autoinjectors<br>10.4.2.3.1. Avonex Pen<br>10.4.2.3.2. PLEGRIDY Pen<br>10.4.2.3.3. Rebif Rebidose<br>10.4.2.3.4. RebiSmart<br>10.4.2.3.5. Rebiject II<br>10.4.2.3.6. ReciGen Physioject<br>10.4.2.4. Interferon <span class=xn-money>-1b</span> Autoinjectors<br>10.4.2.4.1. BETACONNECT<br>10.4.2.4.2. BETAJECT Comfort / Betacomfort<br>10.4.2.4.3. Betaject Lite<br>10.4.2.4.4. ExtaviJect 30G / ExtaviPro 30G<br>10.4.2.5. Other Marketed Autoinjectors<br>10.4.2.5.1. Cinnomer40 Physioject<br>10.4.2.5.2. CSYNC Autoinjector<br>10.4.2.5.3. WhisperJECT<br>10.4.2.5.4. Remurel Autoxon<br>10.4.2.6. Other Dosage Forms<br>10.4.2.7. Historical Sales of Approved Products<br>10.4.2.7.1. Interferon -1a<br>10.4.2.7.2. Interferon <span class=xn-money>-1b</span><br>10.5. Migraine<br>10.5.1. Overview and Epidemiology<br>10.5.2. Available Treatment Options: Sumatriptan Succinate<br>10.5.2.1 History of Development<br>10.5.2.2 Marketed Autoinjectors<br>10.5.2.2.1. ALSUMA<br>10.5.2.2.2. IMITREX STATdose Pen<br>10.5.2.2.3. Zembrace SymTouch<br>10.5.2.2.4. Aimovig SureClick Autoinjector<br>10.5.2.2.5. Emgality Prefilled Pen<br>10.5.5. Other Dosage Forms<br>10.5.6. Historical Sales of Approved Products<br>10.6. Rheumatoid Arthritis<br>10.6.1. Overview and Epidemiology<br>10.6.2. Available Treatment Options<br>10.6.2.1 History of Development<br>10.6.2.2. Marketed Autoinjectors for Rheumatoid Arthritis<br>10.6.2.2.1. Actemra<br>10.6.2.2.2. CIMZIA AutoClicks Prefilled Pen<br>10.6.2.2.3. Enbrel SureClick<br>10.6.2.2.4. Hulio Prefilled Pen<br>10.6.2.2.5. HUMIRA Pen<br>10.6.2.2.6. ORENCIA ClickJect<br>10.6.2.2.7. OTREXUP<br>10.6.2.2.8. Rasuvo Autoinjector<br>10.6.2.2.9. SIMPONI SmartJect Autoinjector<br>10.6.2.2.10. KEVZARA Prefilled Pen<br>10.6.2.2.11. IMRALDI Prefilled Pen<br>10.6.4. Historical Sales of Approved Products</p><p><b>11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS</b><br>11.1. Chapter Overview<br>11.2. Marketed Drug Candidates for Delivery via Autoinjectors<br>11.2.1. Most Likely Drug Candidates<br>11.2.2. Likely Drug Candidates<br>11.2.3. Less Likely Drug Candidates<br>11.2.4. Unlikely Drug Candidates<br>11.3. Clinical Drug Candidates for Delivery via Autoinjectors<br>11.3.1. Most Likely Drug Candidates<br>11.3.2. Likely Drug Candidates<br>11.3.3. Less Likely Drug Candidates<br>11.3.4. Unlikely Drug Candidates</p><p><b>12. KEY PLAYERS</b><br>12.1. Chapter Overview<br>12.2. Antares Pharma<br>12.2.1. Company Overview<br>12.2.2. Financial Information<br>12.2.3. Product Portfolio<br>12.2.3.1. Autoinjectors: Product Details<br>12.2.3.1.1. Vibex<br>12.2.3.1.2. QuickShot<br>12.2.3.1.3. BigShot<br>12.2.4. Key Collaborators<br>12.2.4.1. Teva Pharmaceutical<br>12.2.4.2. Ferring Pharmaceuticals<br>12.2.4.3. AMAG Pharmaceuticals<br>12.2.4.4. JCR Pharmaceuticals<br>12.2.4.5. Pfizer<br>12.2.4.6. Idorsia Pharmaceuticals<br>12.2.5. Recent Developments and Future Outlook<br>12.3 Consort Medical (Previously Bespak)<br>12.3.1. Company Overview<br>12.3.2. Financial Information<br>12.3.3. Technology Overview<br>12.3.4. Product Portfolio<br>12.3.4.1. Autoinjectors: Product Details<br>12.3.4.1.1. Syrina<br>12.3.4.1.2. OTS Autoinjector<br>12.3.4.1.3. Viscala Autoinjector<br>12.3.5. Key Collaborators<br>12.3.5.1. Aesica Pharmaceuticals<br>12.3.5.2. Undisclosed Global Biopharmaceutical Company<br>12.3.5.3. Regeneron Pharmaceuticals<br>12.3.6. Recent Developments and Future Outlook<br>12.4. DALI Medical Devices<br>12.4.1. Company Overview<br>12.4.2. Product Portfolio<br>12.4.2.1. Autoinjectors: Product Details<br>12.4.2.1.1. SAN-L<br>12.4.2.1.2. SAN-P<br>12.4.2.1.3. SAN-DV<br>12.4.2.1.4. SAN-DV Pro<br>12.4.3. Collaborations<br>12.4.3.1. Elcam Medical<br>12.4.4. Recent Developments and Future Outlook<br>12.5. Elcam Medical (E3D Elcam Drug Delivery Devices)<br>12.5.1. Company Overview<br>12.5.2. Product Portfolio<br>12.5.2.1. Autoinjectors: Product Details<br>12.5.2.1.1. Flexi-Q Disposable Autoinjectors<br>12.5.2.1.1.1. Flexi-Q PFS<br>12.5.2.1.1.2. Flexi-Q HV<br>12.5.2.1.1.3. Flexi -Q DV<br>12.5.2.1.2. Flexi-Q Reusable Autoinjectors<br>12.5.2.1.2.1. Flexi-Q mMU<br>12.5.2.1.2.2. Flexi-Q eMU-C / P<br>12.5.2.1.2.3. Flexi-Q EAI<br>12.5.3. Comparison of Elcam Medical Autoinjectors<br>12.5.4. Key Collaborators<br>12.5.4.1. DALI Medical Devices<br>12.5.5. Recent Developments and Future Outlook<br>12.6. Jiangsu Delfu Medical Devices<br>12.6.1. Company Overview<br>12.6.2. Financial Information<br>12.6.3. Product Portfolio<br>12.6.3.1. Autoinjectors: Overview and Specifications<br>12.6.3.1.1. Components of Delfu Autoinjectors<br>12.6.3.1.2. Applications of Delfu Autoinjectors<br>12.6.3.1.3. Features of Delfu Autoinjectors<br>12.6.3.1.4. Advantages of Delfu Autoinjectors<br>12.6.3.1.5. Specifications of Delfu Autoinjectors<br>12.6.3.2. Autoinjectors: Product Details<br>12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector<br>12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector<br>12.6.3.2.3. DZ-IA Auto Injector Pen<br>12.6.3.2.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens<br>12.6.3.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen<br>12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors<br>12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen<br>12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen<br>12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen<br>12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen<br>12.6.4. Recent Developments and Future Outlook<br>12.7. Oval Medical Technologies<br>12.7.1. Company Overview<br>12.7.2. Product Portfolio<br>12.7.2.1. Autoinjectors: Product Details<br>12.7.2.1.1 ArQ<br>12.7.2.1.2 ArQ - Bios<br>12.7.2.1.3 ArQ - Tempo<br>12.7.2.1.4 ArQ - Vita<br>12.7.3. Key Collaborators<br>12.7.3.1. SOLIZE<br>12.7.4. Recent Developments and Future Outlook<br>12.8. <span class=xn-person>Owen Mumford</span><br>12.8.1. Company Overview<br>12.8.2. Product Portfolio<br>12.8.2.1. Autoinjectors: Product Details<br>12.8.2.1.1. Autoject Micro<br>12.8.2.1.2. Autoject 2<br>12.8.2.1.3. Autoject Mini<br>12.8.2.1.4. Autoject Visco<br>12.8.2.1.5. UniSafe Autoinjector<br>12.8.2.1.6. UniSafe Connected Auto-injector<br>12.8.3. Key Collaborators<br>12.8.3.1. Sanofi Aventis<br>12.8.4. Recent Developments and Future Outlook<br>12.9. SHL Group<br>12.9.1. Company Overview<br>12.9.2. Product Portfolio<br>12.9.2.1. Two-Step Disposable Autoinjectors: Product Details<br>12.9.2.1.1 Amber (Pushclick Technology)<br>12.9.2.1.2. Molly<br>12.9.2.1.3. MollyRNS<br>12.9.2.1.4. Molly 2.25<br>12.9.2.1.5. Rotaject<br>12.9.2.1.6. Bertha<br>12.9.2.1.7. DAI 2<br>12.9.2.1.8. Maggie<br>12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors<br>12.9.2.2. Three-Step Disposable Autoinjectors: Product Details<br>12.9.2.2.1. DAI<br>12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism)<br>12.9.2.2.3. VSDI+NIT<br>12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors<br>12.9.2.2.5. PPI Injector (Rotaject Pressure Release Technology)<br>12.9.3. Key Collaborators<br>12.9.3.1. Schreiner MediPharm<br>12.9.3.2. QuiO<br>12.9.4. Recent Developments and Future Outlook<br>12.10. Union Medico<br>12.10.1. Company Overview<br>12.10.2. Technology Overview<br>12.10.3. Product Portfolio<br>12.10.3.1. Autoinjectors: Product Details<br>12.10.3.1.1 45 Autoinjector<br>12.10.3.1.2 45/ S Autoinjector<br>12.10.3.1.3 45/ M Autoinjector<br>12.10.3.1.4 45/ R Autoinjector<br>12.10.3.1.5 Comparison of 45 Autoinjectors<br>12.10.3.1.6 90Autoinjector<br>12.10.3.1.7 90/ S Autoinjector<br>12.10.3.1.8 90/ M Autoinjector<br>12.10.3.1.9 90/ XL Autoinjector<br>12.10.3.1.10 SuperGrip Autoinjector<br>12.10.3.1.11 Exclusive Autoinjector<br>12.10.3.1.12 Comparison of 90 Autoinjectors<br>12.10.4. Recent Developments and Future Outlook<br>12.11. Ypsomed<br>12.11.1. Company Overview<br>12.11.2. Financial Information<br>12.11.3. Product Portfolio<br>12.11.3.1. Autoinjectors: Product details<br>12.11.3.1.1. YpsoMate, YpsoMate 2.25 and YpsoMate 2.25Pro<br>12.11.3.1.2. VarioJect<br>12.11.3.1.3. Comparison of Autoinjectors<br>12.11.4. Key Collaborators<br>12.11.4.1. I-SENS<br>12.11.4.2. <span class=xn-person>Royal Philips</span><br>12.11.4.3. JDRF<br>12.11.5. Recent Developments and Future Outlook</p><p><b>13. EMERGING PLAYERS</b><br>13.1. Chapter Overview<br>13.2. AktiVax<br>13.3. Amneal Pharmaceuticals<br>13.4. kalo<br>13.5. MiniEpi<br>13.6. Nemera<br>13.7. Nuance Designs<br>13.8. Windgap Medical<br>13.9. Xeris Pharmaceuticals<br>13.10. Zion Clinical Pharmacy</p><p><b>14. KOL ANALYSIS</b><br>14.1. Chapter Overview<br>14.2. Methodology<br>14.3. KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials<br>14.3.1. Geographical Distribution of KOLs<br>14.3. KOL Analysis: Patent Assignees</p><p><b>15. SWOT ANALYSIS</b><br>15.1. Chapter Overview<br>15.2. Strengths<br>15.3. Weaknesses<br>15.4. Opportunities<br>15.5. Threats<br>15.6. Concluding Remarks</p><p><b>16. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS</b><br>16.1. Chapter Overview<br>16.2. Challenges Associated with Medical Device Manufacturing<br>16.3. Role of CMOs in Medical Device Manufacturing<br>16.4. Services Offered by Medical Device CMOs<br>16.5. Advantages Offered by Medical Device CMOs<br>16.6. Risks Associated with Outsourcing to CMOs<br>16.7. Drug Delivery Service Providers<br>16.8. Concluding Remarks</p><p><b>17. MARKET SIZING AND OPPORTUNITY ANALYSIS</b><br>17.1. Chapter Overview<br>17.2. Forecast Methodology and Key Assumptions<br>17.3. Global Autoinjectors Market, 2020-2030 (By Value)<br>17.3.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value)<br>17.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value)<br>17.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value)<br>17.3.4. Autoinjectors Market in <span class=xn-location>North America</span>, 2020-2030 (By Value)<br>17.4. Global Autoinjectors Market, 2020-2030 (By Volume)<br>17.5. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value)<br>17.6. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume)<br>17.7. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value)<br>17.8. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume)<br>17.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value)<br>17.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume)<br>17.11. Global Autoinjectors Market for Migraine, 2020-2030 (By Value)<br>17.12. Global Autoinjectors Market for Migraine, 2020-2030 (By Volume)<br>17.13. Global Autoinjectors Market for Diabetes, 2020-2030 (By Value)<br>17.14. Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume)<br>17.15. Global Autoinjectors Market for Other Indications, 2020-2030 (By Value)<br>17.16. Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)</p><p><b>18. CONCLUSION</b><br>18.1. Chapter Overview<br>18.2. Key Takeaways</p><p><b>19. INTERVIEW TRANSCRIPTS</b><br>19.1. Chapter Overview<br>19.2. DALI Medical Devices<br>19.2.1. Company Snapshot<br>19.2.2. Interview Transcript: <span class=xn-person>David Daily</span>, CEO and Co-Founder<br>19.3. PHC<br>19.4. Elcam Medical</p><p><b>20. APPENDIX 1: TABULATED DATA</b></p><p><b>21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS</b><br></p><ul type=disc><li>AbbVie</li><li>AktiVax</li><li>ALK-Abell</li><li>Allergy Therapeutics</li><li>Alvogen</li><li>Alvotech</li><li>AMAG Pharmaceuticals</li><li>AMETEK Engineered Medical Components</li><li>Amgen</li><li>Amneal Pharmaceuticals</li><li>Amsino</li><li>Androsystems</li><li>Antares Pharma</li><li>Apex Medical Technologies</li><li>Asahi Kasei Pharma</li><li>Ascendis Pharma</li><li>AstraZeneca</li><li>Atrion</li><li>B&A Health</li><li>Bausch Health Companies</li><li>Bayer</li><li>BD</li><li>Bespak</li><li>BIOCORP LIFE SCIENCES</li><li>Biogen</li><li>BioGene Pharmaceutical</li><li>Biomerics</li><li>Boehringer Ingelheim</li><li>Bristol-<span class=xn-person>Myers Squibb</span></li><li>Cambridge Consultants</li><li>Canon <span class=xn-location>Virginia</span></li><li>Carclo</li><li>Celltrion</li><li>ChemProtect</li><li>Chugai Pharmaceutical</li><li>CinnaGen</li><li>Cirtec Medical</li><li>Consort Medical</li><li>Contract Medical International</li><li>Creare</li><li>Crossject</li><li>Doctor Pack</li><li>Donatelle</li><li>Dr. Reddy's Laboratory</li><li>DSM</li><li>Duoject Medical Systems</li><li>EA Pharma</li><li>Eastek International</li><li>EG-GILERO</li><li>Eisai</li><li>Elcam Drug Delivery Devices</li><li>Eli Lilly</li><li>EMD Serono</li><li>Europlaz Technologies</li><li>Evergreen Research</li><li>Fabrico Medical</li><li>Ferring Pharmaceuticals</li><li>Flex</li><li>Forefront Medical Technology</li><li>Fresenius Kabi</li><li>Freudenberg Medical</li><li>Fujifilm Kyowa Kirin Biologics</li><li>Genentech</li><li>Gerresheimer</li><li>GlaxoSmithKline</li><li>GW Plastics</li><li>H&T Presspart</li><li>Haselmeier</li><li>Haywood Vocational Opportunities</li><li>Hoffmann-La Roche</li><li>IEC Electronics</li><li>Immunex</li><li>Integer</li><li>Interplex</li><li>Inzign</li><li>Jabil</li><li>Janssen Biotech</li><li>JCR Pharmaceuticals</li><li>Jiangsu Delfu medical device</li><li>Kalo</li><li>King Pharmaceuticals</li><li>Lincoln Medical Centre</li><li>Lineage Therapeutics</li><li>Lupin</li><li>M&M Qualtech</li><li>Mack Molding</li><li>Medac Pharma</li><li>Medeca Pharma</li><li>Medicom Innovation Partner</li><li>Merck</li><li>Meridian Medical Technologies</li><li>Midwest Interventional Systems</li><li>MiniEpi</li><li>Modulus</li><li>Momenta Pharmaceuticals</li><li>Mylan</li><li>NACS</li><li>Natech Plastics</li><li>Nemera</li><li>NeoTech Medical</li><li>Nexeon MedSystems</li><li>Novartis</li><li>Nuance Designs</li><li>Occam Design</li><li>Ology Bioservices</li><li>Oval Medical Technologies</li><li><span class=xn-person>Owen Mumford</span></li><li>P3 Medical</li><li>PA Consulting Group</li><li>Palatin Technologies</li><li>Paramit</li><li>Peridot</li><li>Pfizer</li><li>Pharma Tech</li><li>PHC Injection Device Technologies</li><li>Phillips-Medisize</li><li>Plastikon</li><li>Plexus</li><li>Polyzen</li><li>Precision Engineered Products</li><li>Precision MicroFab</li><li>Preco</li><li>Pro-Dex</li><li>Promius Pharma</li><li>Proven Process Medical Devices</li><li>Providence Enterprise</li><li>Quality Tech Services</li><li>Rafa Laboratories</li><li>RaviMed</li><li>Regeneron Pharmaceuticals</li><li>Riverside Medical Packaging</li><li>Roche</li><li>Rchling Medical</li><li>Samsung Bioepis</li><li>SanaVita Medical</li><li>Sandoz</li><li>Sanmina</li><li>Sanofi</li><li>Shire</li><li>SHL Group</li><li>SMC</li><li>Sovrin Plastics</li><li>Stellartech Research</li><li>SteriPack</li><li>Stevanato Group</li><li>Sumitomo Dainippon Pharma</li><li>Sun Pharmaceutical</li><li>Survival Technologies</li><li>Switchback Medical</li><li>Takeda Pharmaceutical</li><li>Teva Pharmaceutical</li><li>Trelleborg Sealing Solutions</li><li>Trend Technologies</li><li>TRICOR Systems</li><li>UCB Biopharma</li><li>Uman Pharma</li><li>Union Medico</li><li>US WorldMeds</li><li>Valtronic</li><li>VascuTech Medical</li><li>Vaupell</li><li>ViVO Smart Medical Devices</li><li>West Pharmaceutical Services</li><li>Westmed</li><li>Windgap Medical</li><li>Xeris Pharmaceuticals</li><li>YL Biologics</li><li>Ypsomed</li><li>Zenius</li><li>Zion Clinic Pharmacy</li></ul><p>For more information about this report visit https://www.researchandmarkets.com/r/ziiga7</p><p>Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.</p><p><br><b>Media Contact:</b></p><p>Research and Markets<br><span class=xn-person>Laura Wood</span>, Senior Manager<br>press@researchandmarkets.com &nbsp;&nbsp;</p><p>For E.S.T Office Hours Call +1-917-300-0470<br>For U.S./CAN Toll Free Call +1-800-526-8630<br>For GMT Office Hours Call +353-1-416-8900</p><p>U.S. Fax: 646-607-1907<br>Fax (outside U.S.): +353-1-481-1716</p><p id=PURL><img title="Cision ID" width=12 height=12 alt=Cision src=https://cdn.statically.io/img/c212.net/c/img/favicon.png style=margin:auto;display:block;text-align:center;max-width:100%;height:auto> View original content:http://www.prnewswire.com/news-releases/autoinjectors-industry-report-2020-2030-worldwide-markets-products-competitive--patent-analyses-case-studies-key--emerging-players-301006656.html</p><p>SOURCE Research and Markets</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpomaWpvKq6yZ6araeiqHqqusOuqq2qqWK%2FprzOq6tmamBnfW5%2Bj2xnZq%2Bfp7mlw8idnGalkae4psDSZqerp5SqsLW%2FjJympqiVqba1tdWeZKmZpJq7tXnAp5ilsaOawG6vwKycZqukqrGqsdJmop6xXZq6pr7GoqWgZaChrrqx0axkamhibYZygJNvag%3D%3D</p></section></article></main></div><footer><div class=container><span class=copyright>&copy; 2024 ZingVlog - <a rel=license href=http://creativecommons.org/licenses/by/4.0/>CC BY 4.0</a></span></div></footer><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/floating.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>